Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00615199 · ClinicalTrials.gov registry record · Phase 2

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

A Phase 2 study of Crohn's Disease, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
139
Enrollment target
20
Study locations

NCT00615199 is a Phase 2 study of Crohn's Disease that has completed, run by Pfizer. The registered enrollment target is 139 participants, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00615199, a Phase 2 study of Crohn's Disease, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
139 participants
Enrollment target
20
Study locations

Study Summary

This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one of the dose levels to be tested will be more effective than placebo (inactive drug).

Conditions Studied

Crohn's Disease

Interventions

  • DRUG Placebo
  • DRUG CP-690,550

Study Locations (20)

Florida

  • Pfizer Investigational Site - Boca Raton
  • Pfizer Investigational Site - Boca Raton
  • Pfizer Investigational Site - Boca Raton
  • Pfizer Investigational Site - Boca Raton
  • Pfizer Investigational Site - Gainesville
  • Pfizer Investigational Site - Gainesville
  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - Jacksonville
  • Pfizer Investigational Site - St. Petersburg

Colorado

  • Pfizer Investigational Site - Boulder
  • Pfizer Investigational Site - Lakewood
  • Pfizer Investigational Site - Wheat Ridge

Alabama

  • Pfizer Investigational Site - Birmingham
  • Pfizer Investigational Site - Mobile

Maryland

  • Pfizer Investigational Site - Chevy Chase
  • Pfizer Investigational Site - Towson

District of Columbia

  • Pfizer Investigational Site - Washington D.C.

Illinois

  • Pfizer Investigational Site - Chicago

Kansas

  • Pfizer Investigational Site - Wichita

Kentucky

  • Pfizer Investigational Site - Louisville

Trial Details

FieldValue
Enrollment Target 139 participants
Start Date 2008-01
Est. Completion 2009-10
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00615199

The ClinicalTrials.gov registry entry for NCT00615199 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 139 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,393-participant average among 105 other Crohn's Disease trials with a reported enrollment target (94% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00615199 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, Colorado, Alabama.

Frequently Asked Questions

What is clinical trial NCT00615199 about?

NCT00615199 is a clinical study titled "A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease". This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one of the dose levels to be tested will be more effective than placebo (inactive drug).

What is the current status of trial NCT00615199?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 139 participants. The study started on 2008-01. Estimated completion is 2009-10.

What conditions does trial NCT00615199 study?

This clinical trial studies the following conditions: Crohn's Disease.

What interventions are being tested in trial NCT00615199?

The interventions under investigation include: Placebo (DRUG), CP-690,550 (DRUG).

Who is sponsoring clinical trial NCT00615199?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00615199 being conducted?

This trial has 20 study locations across Alabama, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Crohn's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Crohn's Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.